Replies to post #10118 on OncoSec Medical Inc (ONCSQ)

[trading.jeff]

Not uncommon for authors to send their TLD journal to more than one publisher.

When I was in academia, this was considered unethical and a conflict. I was in another field, so, maybe things are different in this one.

I don't think it out of the question that OncoSec could send two different abstracts. We don't know what they might be sitting on.

$ONCS

[trebor4]

No, it is not common at all. in fact it is most uncommon; especially when one of the venues has a strict confidentiality policy. Really not sure why you are fighting this one.

I already spoke with ONCS. They are very tight lipped about ASCO and replied that if they receive any news regarding ASCO they will decide at that time how to move forward.

Considering that we were supposed to receive MCC data last year then YES, I am sure they have enough for a presentation.

[erostratus]

I thought the same thing lasers. Until I read ASCO confidentiality policy.
The possibility for Melanoma to be presented at asco is if they only present P1 data and P2 interim at ASGCT; and present final data at ASCO. But there is no way we have had final data for Mel by time of Abstract submission (trial is still ongoing).
Which pretty much means that Melanoma is out of the question. MCC looks to be it...MCC data must be really good